Head, Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research and University of Western Australia’s Centre for Medical Research, Australia
Associate Professor Kevin Pfleger is Head of Molecular Endocrinology and Pharmacology at the Harry Perkins Institute of Medical Research and University of Western Australia’s Centre for Medical Research. His laboratory studies the molecular pharmacology of receptors, particularly those important in kidney disorders, cardiovascular disease, diabetes complications and cancer. He is a National Health and Medical Research Council RD Wright Biomedical Research Fellow (Level 2), as well as being Chief Scientific Advisor of ASX-listed Dimerix Limited, a spin-out company from the Perkins and UWA that has announced successful Phase 2a clinical trial results for treating chronic kidney disease, particularly associated with diabetes. He was Chief Scientific Officer of Dimerix Bioscience Pty Ltd from 2008-2014. A/Prof Pfleger is Chair of the Executive Committee of Accelerating Australia, a life sciences consortium working to advance the biomedical innovation ecosystem across Australia, supported by the MedTech and Pharma Growth Centre (MTPConnect). He is also Chair of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Scientific Advisory Committee, member of the International Advisory Group of the British Pharmacological Society, member of the Western Australian State Committee of AusBiotech, and serves as the Commercialisation Representative on the Western Australian Health Translation Network Management Committee. He has won numerous awards for his work and service, most recently UWA Innovation Champion 2018.